Viveve, Inc.

Viveve, Inc. is a medical technology company focused on developing and delivering innovative solutions for women's health, particularly in the areas of vaginal rejuvenation and sexual wellness. Founded in 2005 in Sunnyvale, US, Viveve, Inc. specializes in medical technologies aimed at improving women's health.

The company underwent a significant change in 2014 when it completed a merger with PLC Systems and began operating as Viveve Medical. The merger involved the issuance of 4. 69 million shares of common stock. Viveve has raised a total of USD 15.

50 mn through funding, with its latest round being Venture Debt amounting to USD 10. 00 mn, led by Bridge Bank, finalized on October 22, 2015. The firm's total number of deals stands at 8. Viveve specializes in providing medical devices designed for women's health, particularly focusing on non-invasive treatment options for vaginal rejuvenation and sexual wellness.

Their flagship product utilizes patented technology to deliver controlled energy to the vaginal wall, stimulating collagen regeneration, which aims to address conditions such as vaginal laxity and dryness. Viveve's solutions are aimed at clinics and healthcare providers, enabling them to offer advanced treatment options to their patients. The company serves a range of clients across North America and select European markets. In the fiscal year 2020, Viveve reported a revenue of USD 5.

48 mn, with an EBITDA loss of USD 17. 20 mn. The company's revenue model relies on transactions tied to their medical devices, where healthcare providers purchase devices and associated services for their patients. Viveve is poised for future growth, focusing on expanding its product offerings and market reach.

The company is working on developing new medical technologies aimed at enhancing women's health, although specific product details or launch dates remain undisclosed. Plans include targeting expansion into additional European markets by 2023 to increase its footprint. The recent funding from the Venture Debt round will be strategically allocated to support these product development initiatives and market entry strategies.